Related Experiment Video
Updated: Mar 24, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation
Yuan Liu1, Elianna B Amin1, Marty W Mayo2
1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract:
Breast cancer metastasis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer (NSCLC) and other solid tumors, and its loss correlates with increased metastases. We show that BRMS1 is posttranslationally regulated by TNF-induced casein kinase 2 catalytic subunit (CK2α') phosphorylation of nuclear BRMS1 on serine 30 (S30), resulting in 14-3-3ε-mediated nuclear exportation, increased BRMS1 cytosolic expression, and ubiquitin-proteasome-induced BRMS1 degradation. Using our in vivo orthotopic mouse model of lung cancer metastases, we found that mutation of S30 in BRMS1 or the use of the CK2-specific small-molecule inhibitor CX4945 abrogates CK2α'-induced cell migration and invasion and decreases NSCLC metastasis by 60-fold. Analysis of 160 human NSCLC specimens confirmed that tumor CK2α' and cytoplasmic BRMS1 expression levels are associated with increased tumor recurrence, metastatic foci, and reduced disease-free survival. Collectively, we identify a therapeutically exploitable posttranslational mechanism by which CK2α-mediated degradation of BRMS1 promotes metastases in lung cancer. Cancer Res; 76(9); 2675-86. ©2016 AACR.
Insights
Loss of breast cancer metastasis suppressor 1 (BRMS1) in lung cancer promotes metastasis. CK2α
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Breast cancer metastasis suppressor 1 (BRMS1) is downregulated in non-small cell lung cancer (NSCLC), correlating with increased metastasis.
- The precise regulatory mechanisms controlling BRMS1 levels and its role in metastasis remain incompletely understood.
Purpose of the Study:
- To elucidate the posttranslational regulation of BRMS1.
- To investigate the role of BRMS1 regulation in NSCLC metastasis.
- To identify potential therapeutic targets for inhibiting lung cancer metastasis.
Main Methods:
- Investigated BRMS1 posttranslational modification using phosphorylation assays and Western blotting.
- Utilized an in vivo orthotopic mouse model of lung cancer to assess metastasis.
- Analyzed 160 human NSCLC specimens for expression levels of CK2α' and BRMS1.
Main Results:
- Tumor necrosis factor (TNF)-induced phosphorylation of nuclear BRMS1 by casein kinase 2 catalytic subunit (CK2α') on serine 30 (S30) leads to nuclear export.
- This process results in increased cytosolic BRMS1, subsequent degradation via the ubiquitin-proteasome pathway, and enhanced cell migration and invasion.
- CK2α' inhibition or S30 mutation significantly reduced NSCLC metastasis in mice by 60-fold; high CK2α' and cytoplasmic BRMS1 correlated with poor patient outcomes.
Conclusions:
- CK2α'-mediated phosphorylation and degradation of BRMS1 is a key mechanism promoting NSCLC metastasis.
- Targeting this posttranslational modification pathway offers a potential therapeutic strategy to reduce lung cancer spread.
- CK2α' and cytoplasmic BRMS1 levels serve as prognostic biomarkers for NSCLC recurrence and survival.
More Related Videos
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Regulation of Nuclear Protein Sorting
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The Nucleolus